About ANTENGENE-B Company

Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative anti-tumor drugs. Our uniqueness stems from our industry-leading R&D capabilities and differentiated strategic approach to developing new anti-tumor therapies. Our vision is to discover, develop and commercialize the world's first of its kind, the only treatment of its kind, and/or the best of its kind to treat patients without borders and improve their standard of living. Through effective use of resources, outstanding ability in target selection, and differentiated R&D strategies, Deqi Pharmaceutical has established a strong and highly collaborative R&D pipeline composed of 12 products, including two late-stage clinical assets and four early clinical assets. Additionally, we are developing six pre-clinical drugs that focus on innovative targets or mechanisms of action and have the potential to become number one in their class to address huge unmet medical needs. Furthermore, these drugs target key pathways of carcinogenesis and have the potential to be used in combination with each other. Since our establishment, we have established a solid R&D structure in the Asia Pacific region and have clinical research and development capabilities across the Asia Pacific region. At this stage, we are setting up a commercialization team in the Asia Pacific region to support recent product launches. The commercialization team consists of multinational company leaders with extensive commercial experience and senior practitioners with a deep understanding of the dynamics of various local markets.